2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161238
    SARS-CoV-2-IN-79 3030428-11-3 98%
    SARS-CoV-2-IN-79 (Compound 5) is a SARS-CoV-2 inhibitor, with IC50 and CC50 values of 55 μg/mL and 311.6 μg/mL. SARS-CoV-2-IN-79 has the highest antiviral activity against (hCoV-19/Egypt/NRC-03/2020). SARS-CoV-2-IN-79 can be used for the research of COVID-19.
    SARS-CoV-2-IN-79
  • HY-161244
    FGA145 98%
    FGA145 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 3.71 μM, 9.82 μM and 53 nM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA145 reveals a multitarget effects in the antiviral activity.
    FGA145
  • HY-161245
    FGA146 98%
    FGA146 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 2.19 μM, 0.96 μM and 0.87 μM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA146 reveals an antiviral activity against SARS-CoV-2.
    FGA146
  • HY-161258
    Antibacterial agent 181 98%
    Antibacterial agent 181 (Compound 3f) is a potent ciprofloxacin cationic antibacterial agent with low cytotoxicity. The MIC values of Antibacterial agent 181 against Staphylococcus aureus and Escherichia coli are both 2 μg/mL.
    Antibacterial agent 181
  • HY-161261
    SARS-CoV-2-IN-81 98%
    SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC50 value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against SARS-CoV-2. SARS-CoV-2-IN-81 attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection.
    SARS-CoV-2-IN-81
  • HY-161263
    Antibacterial agent 182 98%
    Antibacterial agent 182 (compound 8c) is an antibacterial agent that shows antibacterial activity against various Gram-positive bacteria, particularly against Vancomycin-resistant Enterococcus faecalis (MIC ≤0.125 μg/mL). Antibacterial agent 182 inhibits biofilm formation of Staphylococcus aureus and Pseudomonas aeruginosa at sub-MIC doses.
    Antibacterial agent 182
  • HY-161264
    Antiviral agent 49 98%
    Antiviral agent 49 (compound 4q) is dual antiviral and antibacterial agent. Antiviral agent 49 shows anti-enterococcus activity and anti-staphylococcal activity.
    Antiviral agent 49
  • HY-161270
    HIV-1 protease-IN-13 98%
    HIV-1 protease-IN-13 (compound 18d) is a potent HIV-1 protease inhibitor with an IC50 value of 0.54 nM. HIV-1 protease-IN-13 also shows potent activity against HIV-1DRVRS (DRV-resistant mutation) and HIV-1NL4_3 variant (wild type).
    HIV-1 protease-IN-13
  • HY-161279
    Antibiofilm agent-5 98%
    Antibiofilm agent-5 (compound 6c) is a multitargeting antibacterial agent with potent antibiofilm activity. Antibiofilm agent-5 could induce metabolic dysfunction by deactivating lactate dehydrogenase and promote the accumulation of reactive oxygen species to decrease the reduced glutathione and ultimately cause oxidative damage in bacteria. Antibiofilm agent-5 can be used for the research of refractory biofilm-intensified bacterial infections.
    Antibiofilm agent-5
  • HY-161299
    LAPTc-IN-1 930898-33-2 98%
    LAPTc-IN-1 (compound 4) is a competitive inhibitor targeting acidic M17 leucinopeptidase (LAPTc) with Ki=0.27 μM. LAPTc-IN-1 is a potential antagonist of the parasite Trypanosoma cruzi.
    LAPTc-IN-1
  • HY-161300
    Antibacterial agent 191 98%
    Antibacterial agent 191 (compound 11a) is a potent semi-synthetic antibiotic. Antibacterial agent 191 exhibits preferable metabolic stability.
    Antibacterial agent 191
  • HY-161309
    RUPB-61 3032827-64-5 98%
    RUPB-61 is a potent Plasmodium falciparum cGMP-dependent protein kinase (PfPKG) inhibitor with an IC50 value of 13 nM. RUPB-61 shows antiparasitic activity.
    RUPB-61
  • HY-161310
    Metallo-β-lactamase-IN-15 1804934-57-3 98%
    Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC50 values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively.
    Metallo-β-lactamase-IN-15
  • HY-161312
    Antifungal agent 93 98%
    Antifungal agent 93 (compound 10) is a potent antifungal agent. Antifungal agent 93 shows antimicrobial activity.
    Antifungal agent 93
  • HY-161325
    Antileishmanial agent-26 98%
    Antileishmanial agent-26 (Compound 69) is a guanidine-containing compound with anti-Leishmania donovani activity. Its IC50 value against Leishmania donovani is 5.67 μM, and its CC50 value against THP-1 is 3.79 μM. Antileishmanial agent-26 can be used in the research of tropical diseases.
    Antileishmanial agent-26
  • HY-161327
    HBV-IN-44 98%
    HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC50 value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro.
    HBV-IN-44
  • HY-161342
    CTSL/CAPN1-IN-2 2410075-64-6 98%
    CTSL/CAPN1-IN-2 (Compound 14b) is an orally active inhibitor of both CTSL and CAPN1, with IC50 values of 6.88 nM and 347.6 nM, respectively. CTSL/CAPN1-IN-2 possesses anti-inflammatory properties and favorable pharmacokinetic characteristics. CTSL/CAPN1-IN-2 exhibits broad-spectrum antiviral activity against coronaviruses by blocking viral entry.
    CTSL/CAPN1-IN-2
  • HY-161352
    NPI52 1429218-68-7 98%
    NPI52 (Compound E1) is a foot-and-mouth disease virus 3C protease (FMDV 3Cpro) inhibitor, with IC50 values of 0.05 and 0.11 µM in FRET and cell-based assay, respectively.
    NPI52
  • HY-161365
    PLpro-IN-2 98%
    PLpro-IN-2 (Compound 16) is an inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 0.25 μM.
    PLpro-IN-2
  • HY-161375
    SDH-IN-13 2975187-87-0 98%
    SDH-IN-13 (Compound 5IIIh) is a SDH inhibitor (IC50: 13.7 μg/mL) and an antifungal agent.
    SDH-IN-13
Cat. No. Product Name / Synonyms Application Reactivity